Hepatitis B Virus Reactivation during Treatment with Multi-Tyrosine Kinase Inhibitor for Hepatocellular Carcinoma
Open Access
- 28 September 2012
- journal article
- Published by S. Karger AG in Case Reports in Oncology
- Vol. 5 (3), 515-519
- https://doi.org/10.1159/000342913
Abstract
Hepatitis B virus (HBV) reactivation is well documented in individuals with cancer who receive certain cytotoxic or immunosuppressive therapies including rituximab treatment. As a general rule, the risk is greatest upon withdrawal of chemotherapy. The risk ranges from approximately 20 to 50% among HBsAg-positive carriers. A 67-year-old man was diagnosed with inoperable multiple hepatocellular carcinoma accompanied by an increase in alpha-fetoprotein and protein induced by vitamin K absence or antagonist II level. Eighteen weeks after starting on the oral multi-tyrosine kinase inhibitor TSU-68, laboratory investigations showed a substantial increase in serum transaminase levels (AST: 302 IU/l; ALT: 324 IU/l) and an elevation of the HBV-DNA level (6.9 log copies/ml). The diagnosis was that the cause of the acute hepatitis was HBV reactivation and we immediately administered entecavir. Two months after the initiation of daily entecavir treatment, laboratory findings showed that the serum levels of transaminases and ALP had improved (AST: 18 IU/l; ALT: 10 IU/l; ALP: 197 U/l). When the HBV markers were examined 4 months later, they were altered: HBeAg was negative and HBeAb was positive. Entecavir treatment was discontinued after 6 months. Although reactivation with rituximab has been reported, reactivation with a tyrosine kinase inhibitor is extremely unusual in a patient who is HBsAg negative but anti-HBc positive. This is the first report describing HBV reactivation with an increasing HBV-DNA level in a HBsAg-negative/HBcAb-positive/HBsAb-positive patient who was treated with TSU-68 for hepatocellular carcinoma.Keywords
This publication has 14 references indexed in Scilit:
- A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinomaCancer Chemotherapy and Pharmacology, 2010
- Chronic hepatitis B: Update 2009Hepatology, 2009
- Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series reportHaematologica, 2009
- Hepatitis B Virus Reactivation in Lymphoma Patients With Prior Resolved Hepatitis B Undergoing Anticancer Therapy With or Without RituximabJournal of Clinical Oncology, 2009
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Entecavir Therapy for up to 96 Weeks in Patients With HBeAg-Positive Chronic Hepatitis BGastroenterology, 2007
- Hepatitis B virus reactivation and alemtuzumab therapyEuropean Journal of Haematology, 2005
- Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxisGut, 2004
- Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphomaHepatology, 2003
- A Hepatitis B Virus Mutant Associated with an Epidemic of Fulminant HepatitisNew England Journal of Medicine, 1991